Vera Therapeutics to Present Final ORIGIN 3 Data on TRUTAKNA in IgA Nephropathy at ASN Kidney Week 2026 — Vera Therapeutics, Inc.

Event summary

Vera Therapeutics will present final efficacy analysis of the ORIGIN 3 trial of TRUTAKNA in IgA nephropathy during the opening plenary session at ASN Kidney Week 2026 on October 22.
Interim results from the PIONEER trial for IgAN and primary membranous nephropathy will also be presented as a late-breaking oral presentation.
Five Vera-sponsored abstracts will be presented at the conference, highlighting the company's focus on autoimmune kidney disease.
TRUTAKNA is currently approved under accelerated approval for reducing proteinuria in IgAN, with continued approval contingent on confirmatory trial results.

The big picture

Vera Therapeutics is positioning itself as a leader in autoimmune kidney disease treatment with a focus on IgA nephropathy. The upcoming presentations at ASN Kidney Week 2026 are critical for validating TRUTAKNA's efficacy and supporting its commercial potential. The company's strategy hinges on expanding the drug's indications and demonstrating long-term clinical benefits to secure sustained market approval and payer coverage.

What we're watching

Clinical Validation: Whether the final ORIGIN 3 data will confirm TRUTAKNA's long-term clinical benefit in IgAN, crucial for maintaining its accelerated approval status.
Market Expansion: How Vera Therapeutics will leverage positive data to expand TRUTAKNA's use into other glomerular diseases, as suggested by the PIONEER trial results.
Competitive Positioning: The pace at which Vera can differentiate TRUTAKNA in the growing autoimmune kidney disease market, particularly against emerging therapies.